Full Text
The Full Text of this article is available as a PDF (96.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Drazen J. M., Yandava C. N., Dubé L., Szczerback N., Hippensteel R., Pillari A., Israel E., Schork N., Silverman E. S., Katz D. A. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999 Jun;22(2):168–170. doi: 10.1038/9680. [DOI] [PubMed] [Google Scholar]
- Evans D. J., Taylor D. A., Zetterstrom O., Chung K. F., O'Connor B. J., Barnes P. J. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med. 1997 Nov 13;337(20):1412–1418. doi: 10.1056/NEJM199711133372002. [DOI] [PubMed] [Google Scholar]
- Greening A. P., Ind P. W., Northfield M., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994 Jul 23;344(8917):219–224. doi: 10.1016/s0140-6736(94)92996-3. [DOI] [PubMed] [Google Scholar]
- Grünberg K., Timmers M. C., de Klerk E. P., Dick E. C., Sterk P. J. Experimental rhinovirus 16 infection causes variable airway obstruction in subjects with atopic asthma. Am J Respir Crit Care Med. 1999 Oct;160(4):1375–1380. doi: 10.1164/ajrccm.160.4.9810083. [DOI] [PubMed] [Google Scholar]
- Malmstrom K., Rodriguez-Gomez G., Guerra J., Villaran C., Piñeiro A., Wei L. X., Seidenberg B. C., Reiss T. F. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med. 1999 Mar 16;130(6):487–495. doi: 10.7326/0003-4819-130-6-199903160-00005. [DOI] [PubMed] [Google Scholar]
- Pauwels R. A., Löfdahl C. G., Postma D. S., Tattersfield A. E., O'Byrne P., Barnes P. J., Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997 Nov 13;337(20):1405–1411. doi: 10.1056/NEJM199711133372001. [DOI] [PubMed] [Google Scholar]
- Reddel H., Ware S., Marks G., Salome C., Jenkins C., Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet. 1999 Jan 30;353(9150):364–369. doi: 10.1016/S0140-6736(98)06128-5. [DOI] [PubMed] [Google Scholar]
- Sont J. K., Willems L. N., Bel E. H., van Krieken J. H., Vandenbroucke J. P., Sterk P. J. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1043–1051. doi: 10.1164/ajrccm.159.4.9806052. [DOI] [PubMed] [Google Scholar]
- Tattersfield A. E., Postma D. S., Barnes P. J., Svensson K., Bauer C. A., O'Byrne P. M., Löfdahl C. G., Pauwels R. A., Ullman A. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med. 1999 Aug;160(2):594–599. doi: 10.1164/ajrccm.160.2.9811100. [DOI] [PubMed] [Google Scholar]
- Ukena D., Harnest U., Sakalauskas R., Magyar P., Vetter N., Steffen H., Leichtl S., Rathgeb F., Keller A., Steinijans V. W. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J. 1997 Dec;10(12):2754–2760. doi: 10.1183/09031936.97.10122754. [DOI] [PubMed] [Google Scholar]
- Woolcock A., Lundback B., Ringdal N., Jacques L. A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996 May;153(5):1481–1488. doi: 10.1164/ajrccm.153.5.8630590. [DOI] [PubMed] [Google Scholar]